Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions

Summary: Emerging evidence suggests that ADP-ribosylation factor like-4c (Arl4c) may be a potential choice for cancer treatment. However, its role in pancreatic cancer, especially in tumor-stroma interactions and drug resistance, is still unknown. In the current study, we examined the proliferation...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xin Chen, Yanzhen Zhang, Weikun Qian, Liang Han, Wei Li, Wanxing Duan, Zheng Wu, Zheng Wang, Qingyong Ma
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Q
Acceso en línea:https://doaj.org/article/c870e6ed27ce479db65dfcc739daa263
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!